ProSciento, OWL metabolomics team up on NAFLD/NASH trial recruitment
ProSciento and OWL Metabolomics are partnering to find eligible participants for clinical trials for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Carolina Henriques, — 
Articles by Carolina Henriques
Digital Support Platform IO Loop Keeps Oncologists and Patients Engaged Throughout Treatment
A new digital support platform, IO Loop, is helping patients stay connected online with doctors before, during, and after treatment. This helps patients track symptoms,…
Intercept Receives NORD Innovation Award for Ocaliva Therapy to Treat Rare Liver Disease
The National Organization for Rare Disorders (NORD) gave its 2017 Industry Innovation Award to Intercept Pharmaceuticals for the company’s primary biliary cholangitis (PBC) drug …
DUR-928 Developer Durect Joins with Sandoz on Posimir Pain Reliever System Efforts
Durect has signed an agreement with Sandoz to develop and market Posimir (Saber-bupivacaine), an investigational localized pain reliever, in the United States. Durect…
New ‘Liver Line’ Online Community to Share Updates on Health, Research, Treatments
A new online community, called Liver Line and sponsored by Galectin Therapeutics, offers the latest information on liver health and research into liver diseases. On Liver…
Exposure to High-Fat Diet in Womb and During Breastfeeding Linked to Liver Disease
A child exposed to a mother’s high-fat diet while in the womb and breastfeeding is at greater risk of developing non-alcoholic fatty liver disease (NAFLD)…
Albireo Hosts NYC Breakfast to Discuss A4250 Therapy for Pediatric Liver Diseases
Boston-based Albireo Pharma hosted an April 13 breakfast presentation in New York that featured an overview of the company’s clinical programs as well as a talk by…